CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Millions	Sep. 30, 2018	Dec. 31, 2017
Current Assets:
Cash and cash equivalents	$ 5,408	$ 5,421
Marketable securities	1,422	1,391
Receivables	5,871	6,300
Inventories	1,282	1,166
Prepaid Expense, Current	886	576
Total Current Assets	14,869	14,854
Property, plant and equipment	5,092	5,001
Goodwill	6,686	6,863
Other intangible assets	1,107	1,210
Deferred income taxes	1,627	1,610
Marketable securities	2,017	2,480
Other assets	2,336	1,533
Total Assets	33,734	33,551
Current Liabilities:
Short-term debt obligations	1,620	987
Accounts payable	1,773	2,248
Accrued liabilities	5,853	6,014
Deferred income	93	83
Income taxes payable	355	231
Total Current Liabilities	9,694	9,563
Deferred Income	486	454
Income taxes payable	3,112	3,548
Pension and other liabilities	1,005	1,164
Long-term debt	5,687	6,975
Total Liabilities	19,984	21,704
Commitments and Contingencies
Bristol-Myers Squibb Company Shareholders' Equity:
Preferred stock	0	0
Common stock	221	221
Capital in excess of par value of stock	2,029	1,898
Accumulated other comprehensive loss	(2,326)	(2,289)
Retained earnings	33,292	31,160
Less cost of treasury stock	(19,576)	(19,249)
Total Bristol-Myers Squibb Company Shareholders' Equity	13,640	11,741
Noncontrolling interest	110	106
Total Equity	13,750	11,847
Total Liabilities and Equity	$ 33,734	$ 33,551